Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26315535 | 0.79 | TRPV1 (0.40) | TRPV1NPC1RAB9A | |
| SCHEMBL21363462 | 0.70 | NTRK1 (0.36) | NPC1RAB9A | |
| SCHEMBL13265535 | 0.69 | ALDH1A1 (0.40) | ALOX5APFEN1RIPK2NPC1MAPK1 | |
| SCHEMBL761133 | 0.69 | ALDH1A1 (0.45) | TRPV1ALOX5APFEN1RIPK2NPC1 | |
| SCHEMBL24037602 | 0.67 | ALDH1A1 (0.38) | ALOX5APFEN1RIPK2MAPK1 | |
| SCHEMBL21497445 | 0.67 | NPC1 (0.38) | TRPV1RIPK2NPC1RAB9A | |
| SCHEMBL19262922 | 0.67 | SCN10A (0.38) | — | |
| SCHEMBL22330400 | 0.66 | SCN10A (0.37) | — | |
| SCHEMBL25515913 | 0.66 | RAB9A (0.39) | TRPV1NPC1GAAMAPK1RAB9A | |
| SCHEMBL24366298 | 0.65 | TRPV1 (0.39) | TRPV1NPC1GAAMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | TRPV1 575/4885ALOX5AP 2726/4885FEN1 1162/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | TRPV1 575/4885ALOX5AP 2726/4885FEN1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.